MovDisordV3, Main, Exploration, bibRecord, 004534

Clozapine withdrawal symptoms in a Parkinson's disease patient

Identifieur interne : 004534 ( Main/Exploration ); précédent : 004533; suivant : 004535

Clozapine withdrawal symptoms in a Parkinson's disease patient

Auteurs : Theresa A. Zesiewicz [États-Unis] ; Sujatha Borra [États-Unis] ; Robert A. Hauser [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2002-11.

RBID : ISTEX:7B174F4E7F3C8D8F95ECC98CD4A5D8391D2A0CB4

Descripteurs français

Pascal (Inist)
- Clozapine, Dibenzodiazépine, Etude cas, Evolution, Homme, Hypertonie spastique, Myoclonie, Neuroleptique, Parkinson maladie, Physiopathologie, Sevrage syndrome, Sérotoninergique syndrome, Tremblement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Carbidopa (adverse effects), Carbidopa (therapeutic use), Case study, Clozapine, Clozapine (adverse effects), Clozapine (therapeutic use), Dose-Response Relationship, Drug, Drug Combinations, Drug Interactions, Drug Therapy, Combination, Evolution, Hallucinations (chemically induced), Hallucinations (drug therapy), Human, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Myoclonus, Neuroleptic, Neurologic Examination, Parkinson Disease (drug therapy), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (diagnosis), Parkinson disease, Pathophysiology, Serotonin syndrome, Spasticity, Substance Withdrawal Syndrome (diagnosis), Tremor, Withdrawal syndrome, clozapine, rebound, serotonin syndrome, withdrawal.
MESH :
- chemical , adverse effects : Antipsychotic Agents, Carbidopa, Clozapine, Levodopa.
- chemical , therapeutic use : Antipsychotic Agents, Carbidopa, Clozapine, Levodopa.
- chemically induced : Hallucinations, Parkinson Disease, Secondary.
- diagnosis : Parkinson Disease, Secondary, Substance Withdrawal Syndrome.
- drug therapy : Hallucinations, Parkinson Disease.
- Aged, Dose-Response Relationship, Drug, Drug Combinations, Drug Interactions, Drug Therapy, Combination, Humans, Male, Neurologic Examination.

Abstract

Abrupt clozapine withdrawal can cause rebound psychosis and severe somatic symptoms in psychiatric patients. We report on the case of an advanced Parkinson's disease patient who developed myoclonus, tremor, rigidity, hyperreflexia, and stupor after abrupt clozapine withdrawal. The patient's symptoms resolved with treatment with cyproheptadine. This clinical picture suggests serotonergic rebound as an explanation for the patient's symptoms, although other pharmacological mechanisms are possible. Clozapine should be gradually withdrawn over a period of 1 to 2 weeks when possible, and abruptly discontinued only when necessary. © 2002 Movement Disorder Society

Url:

https://api.istex.fr/document/7B174F4E7F3C8D8F95ECC98CD4A5D8391D2A0CB4/fulltext/pdf

DOI: 10.1002/mds.10282

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clozapine withdrawal symptoms in a Parkinson's disease patient</title>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
</author>
<author><name sortKey="Borra, Sujatha" sort="Borra, Sujatha" uniqKey="Borra S" first="Sujatha" last="Borra">Sujatha Borra</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7B174F4E7F3C8D8F95ECC98CD4A5D8391D2A0CB4</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10282</idno>
<idno type="url">https://api.istex.fr/document/7B174F4E7F3C8D8F95ECC98CD4A5D8391D2A0CB4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001748</idno>
<idno type="wicri:Area/Istex/Curation">001748</idno>
<idno type="wicri:Area/Istex/Checkpoint">002E26</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Zesiewicz T:clozapine:withdrawal:symptoms</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12465085</idno>
<idno type="wicri:Area/PubMed/Corpus">003894</idno>
<idno type="wicri:Area/PubMed/Curation">003894</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003B57</idno>
<idno type="wicri:Area/Ncbi/Merge">000957</idno>
<idno type="wicri:Area/Ncbi/Curation">000957</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000957</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Zesiewicz T:clozapine:withdrawal:symptoms</idno>
<idno type="wicri:Area/Main/Merge">006540</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:03-0038232</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002604</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000717</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002825</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Zesiewicz T:clozapine:withdrawal:symptoms</idno>
<idno type="wicri:Area/Main/Merge">006864</idno>
<idno type="wicri:Area/Main/Curation">004534</idno>
<idno type="wicri:Area/Main/Exploration">004534</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clozapine withdrawal symptoms in a Parkinson's disease patient</title>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Parkinson's Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Borra, Sujatha" sort="Borra, Sujatha" uniqKey="Borra S" first="Sujatha" last="Borra">Sujatha Borra</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Parkinson's Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Parkinson's Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, Parkinson's Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-11">2002-11</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1365">1365</biblScope>
<biblScope unit="page" to="1367">1367</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">7B174F4E7F3C8D8F95ECC98CD4A5D8391D2A0CB4</idno>
<idno type="DOI">10.1002/mds.10282</idno>
<idno type="ArticleID">MDS10282</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Carbidopa (adverse effects)</term>
<term>Carbidopa (therapeutic use)</term>
<term>Case study</term>
<term>Clozapine</term>
<term>Clozapine (adverse effects)</term>
<term>Clozapine (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Combinations</term>
<term>Drug Interactions</term>
<term>Drug Therapy, Combination</term>
<term>Evolution</term>
<term>Hallucinations (chemically induced)</term>
<term>Hallucinations (drug therapy)</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Myoclonus</term>
<term>Neuroleptic</term>
<term>Neurologic Examination</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (diagnosis)</term>
<term>Parkinson disease</term>
<term>Pathophysiology</term>
<term>Serotonin syndrome</term>
<term>Spasticity</term>
<term>Substance Withdrawal Syndrome (diagnosis)</term>
<term>Tremor</term>
<term>Withdrawal syndrome</term>
<term>clozapine</term>
<term>rebound</term>
<term>serotonin syndrome</term>
<term>withdrawal</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Carbidopa</term>
<term>Clozapine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Carbidopa</term>
<term>Clozapine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hallucinations</term>
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease, Secondary</term>
<term>Substance Withdrawal Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hallucinations</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Combinations</term>
<term>Drug Interactions</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Male</term>
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Clozapine</term>
<term>Dibenzodiazépine</term>
<term>Etude cas</term>
<term>Evolution</term>
<term>Homme</term>
<term>Hypertonie spastique</term>
<term>Myoclonie</term>
<term>Neuroleptique</term>
<term>Parkinson maladie</term>
<term>Physiopathologie</term>
<term>Sevrage syndrome</term>
<term>Sérotoninergique syndrome</term>
<term>Tremblement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abrupt clozapine withdrawal can cause rebound psychosis and severe somatic symptoms in psychiatric patients. We report on the case of an advanced Parkinson's disease patient who developed myoclonus, tremor, rigidity, hyperreflexia, and stupor after abrupt clozapine withdrawal. The patient's symptoms resolved with treatment with cyproheptadine. This clinical picture suggests serotonergic rebound as an explanation for the patient's symptoms, although other pharmacological mechanisms are possible. Clozapine should be gradually withdrawn over a period of 1 to 2 weeks when possible, and abruptly discontinued only when necessary. © 2002 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
</region>
<name sortKey="Borra, Sujatha" sort="Borra, Sujatha" uniqKey="Borra S" first="Sujatha" last="Borra">Sujatha Borra</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004534 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004534 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:7B174F4E7F3C8D8F95ECC98CD4A5D8391D2A0CB4
   |texte=   Clozapine withdrawal symptoms in a Parkinson's disease patient
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Clozapine withdrawal symptoms in a Parkinson's disease patient

Clozapine withdrawal symptoms in a Parkinson's disease patient

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.